CooperSurgical Announces FDA Clearance for the Wallace® Aspiration Pump
TRUMBULL, Conn., August 24, 2026 – CooperSurgical, a global leader in women’s health and fertility, today announces that the U.S Food and Drug Administration (FDA) has granted clearance for the Wallace® Aspiration Pump.
The Wallace® Aspiration Pump is designed to support predictable aspiration through stable pressure management and consistent device behavior during oocyte retrieval.1,2
Developed for and with clinicians, no other pump features a modern digital touch screen that is easy to use and is intuitive, with 2 preset pressure setting options for 2 types of needles3, and additional customizations like language, screen brightness and more.
This milestone represents an advancement in fertility care and reflects the company’s commitment to delivering innovative products that support fertility clinic efficiency.
“Today is a meaningful moment for CooperSurgical,” said Roula Halabi, Head of Global Fertility Solutions for CooperSurgical. “We are uniting an ecosystem of innovation that is accelerating the possibilities in fertility care for generations to come.”
CooperSurgical will now move forward with commercialization to provide availability of the pump throughout the United States.
About CooperSurgical
CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most in life. We are at the forefront of delivering innovative assisted reproductive technology (ART) and genomic solutions that enhance the work of ART professionals to the benefit of families. We currently offer more than 600 clinically relevant medical devices to women’s healthcare providers, including testing and treatment options.
CooperSurgical is a wholly owned subsidiary of CooperCompanies (Nasdaq: COO). Headquartered in Trumbull, Connecticut, we produce and market a wide array of products and services for use by women’s healthcare clinicians.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.
Media Contact:
CooperSurgical
[email protected]
References
1. ESHRE Working Group on Ultrasound in ART, D’Angelo, A., et al. (2019). Recommendations for good practice in ultrasound: oocyte pick-up. Human Reproduction Open, (4), hoz025.
2. Cohen, J., et al. (1986). Follicular aspiration using a syringe suction system may damage the zona pellucida. Journal of In Vitro Fertilization and Embryo Transfer. 3, pp.224–226.
3. CooperSurgical data on file.